Background: Sepsis is a condition in patients with systemic infections that leads to organ dysfunction. High mortality in sepsis requires better markers for initial treatment. Interleukin-17 is a pro-inflammatory cytokine produced by Th-17 cells that play a role in inflammation processes. There are different study results regarding the role of IL-17 in septic patients. This study aimed to prove the role of IL-17 on the clinical outcomes of septic patients. Methods: This study used a systematic review and meta-analysis design. Data were obtained by searching articles published between January 2001 and June 2022 in Pubmed, ScienceDirect, Scopus, and Medline databases to evaluate Interleukin-17 on clinical outcomes in septic patients. Only human studies were used in this study. Meta-analysis was undertaken using random effects models. Results: Fourteen published studies were eligible, and four studies were included in the meta-analysis. Meta-analysis of the ratio of means (RoM) IL-17 concentration demonstrated a 5.96-fold higher level in non-survivor septic patients compared with survivors (four studies; n = 194 patients; RoM=5.96; 95% CI, 3.51-10.31; p < 0.00001; I2 = 92%) Conclusion: IL-17 levels were significantly elevated in non-survivor and predicted mortality of septic patients.